Australia's Avexa has been wooing investors recently over the prospects of its late-stage HIV therapy, and the added attention has paid off with a spike in its stock price. Avexa shares jumped 23 percent, rising to 19 cents, as it readies a presentation on a Phase III trial of its apricitabine HIV treatment. "We've just been talking to people about that, and that's created some interest within the market," Avexa CEO Julian Chick told Bloomberg. Report